Issue link: http://www.e-digitaleditions.com/i/686898
Inhalation JUNE 2016 21 14. Chattoraj S, Shi L, Sun CC, 2011. Profoundly improving flow properties of a cohesive cellulose powder by surface coating with nano-silica through comilling. Journal of Pharmaceutical Sciences 100(11):4943- 4952. 15. Zhou Q, Armstrong B, Larson I, Stewart PJ, Mor- ton DA, 2010. Improving powder flow properties of a cohesive lactose monohydrate powder by intensive mechanical dry coating. Journal of Pharmaceutical Sci- ences 99(2):969-981. 16. Zhou Q, Armstrong B, Larson I, Stewart PJ, Mor- ton DA, 2010. Effect of host particle size on the modifi- cation of powder flow behaviours for lactose monohy- drate following dry coating. Dairy Science & Technol- ogy 90(2-3):237-251. 17. Zhou QT, Qu L, Gengenbach T, Denman JA, Lar- son I, Stewart PJ, Morton DA, 2011. Investigation of the extent of surface coating via mechanofusion with varying additive levels and the influences on bulk pow- der flow properties. International Journal of Pharmaceu- tics 413(1):36-43. 18. Stank K, Steckel H, 2013. Physico-chemical charac- terisation of surface modified particles for inhalation. International Journal of Pharmaceutics 448(1):9-18. 19. Zhou QT, Qu L, Gengenbach T, Larson I, Stewart PJ, Morton DA, 2013. Effect of surface coating with magnesium stearate via mechanical dry powder coating approach on the aerosol performance of micronized drug powders from dry powder inhalers. AAPS Pharm- SciTech 14(1):38-44. 20. Morton D, 2005. Dry powder inhaler formulations comprising surface-modified particles with anti-adher- ent additives: International Patent Application WO/2006/056812. 21. Staniforth J, Morton D, 2001. Pharmaceutical com- positions for inhalation: International Patent Applica- tion WO/2002/043702. 22. Morton D, Ganderton D, Staniforth J, Tobyn M, Eason S, Harmer Q, 2004. Dry powder composition comprising a benzodiazepine for pulmonary inhalation: I n t e r n a t i o n a l P a t e n t A p p l i c a t i o n W O / 2 0 0 5 / 025541. 23. Begat P, Price R, Harris H, Morton DA, Staniforth JN, 2005. The influence of force control agents on the cohesive-adhesive balance in dry powder inhaler formu- lations. Kona Powder and Particle Journal 23:109-121. 24. Begat P, Morton DA, Shur J, Kippax P, Staniforth JN, Price R, 2009. The role of force control agents in high-dose dry powder inhaler formulations. Journal of Pharmaceutical Sciences 98(8):2770-2783. 25. Kumon M, Suzuki M, Kusai A, Yonemochi E, Ter- ada K, 2006. Novel approach to DPI carrier lactose with mechanofusion process with additives and evaluation by I G C . C h e m i c a l a n d P h a r m a c e u t i c a l B u l l e t i n 54(11):1508-1514. 26. Kumon M, Machida S, Suzuki M, Kusai A, Yonemochi E, Terada K, 2008. Application and mech- References 1. Telko MJ, Hickey AJ, 2005. Dry powder inhaler for- mulation. Respiratory Care 50(9):1209-1227. 2. Jones MD, Young P, Traini D, 2012. The use of inverse gas chromatography for the study of lactose and pharmaceutical materials used in dry powder inhalers. Advanced Drug Delivery Reviews 64(3):285-293. 3. De Boer A, Chan H, Price R, 2012. A critical view on lactose-based drug formulation and device studies for dry powder inhalation: Which are relevant and what interactions to expect? Advanced Drug Delivery Reviews 64(3):257-274. 4. Srichana T, Martin GP, Marriott C, 1998. Dry powder inhalers: The influence of device resistance and powder formulation on drug and lactose deposition in vitro. Euro- pean Journal of Pharmaceutical Sciences 7(1):73-80. 5. Zhou QT, Leung SSY, Tang P, Parumasivam T, Loh ZH, Chan H-K, 2014. Inhaled formulations and pul- monary drug delivery systems for respiratory infections. Advanced Drug Delivery Reviews 85: 83-99. 6. Lin Y-W, Wong J, Qu L, Chan H-K, Zhou QT, 2015. Powder production and particle engineering for dry powder inhaler formulations. Current Pharmaceu- tical Design 21(27):3902-3916. 7. Brodka-Pfeiffer K, Häusler H, Graß P, Langguth P, 2003. Conditioning following powder micronization: Influence on particle growth of salbutamol sulfate. Drug Development and Industrial Pharmacy 29(10):1077- 1084. 8. Das S, Larson I, Young P, Stewart P, 2009. Surface energy changes and their relationship with the dis- persibility of salmeterol xinafoate powders for inhalation after storage at high RH. European Journal of Pharma- ceutical Sciences 38(4):347-354. 9. Chan LW, Lim LT, Heng PW, 2003. Immobiliza- tion of fine particles on lactose carrier by precision coat- ing and its effect on the performance of dry powder for- mulations. Journal of Pharmaceutical Sciences 92(5):975-984. 10. Tang ES, Chan L, Heng PW, 2005. Coating of mul- tiparticulates for sustained release. American Journal of Drug Delivery 3(1):17-28. 11. Zhou QT, Morton DA, 2012. Drug–lactose bind- ing aspects in adhesive mixtures: Controlling perfor- mance in dry powder inhaler formulations by altering lactose carrier surfaces. Advanced Drug Delivery Reviews 64(3):275-284. 12. Pfeffer R, Dave RN, Wei D, Ramlakhan M, 2001. Synthesis of engineered particulates with tailored prop- erties using dry particle coating. Powder Technology 117(1):40-67. 13. Otles S, Lecoq O, Dodds J, 2011. Dry particle high coating of biopowders: An energy approach. Powder Technology 208(2):378-382.